Clinically isolated syndrome (CIS) usually describes a first clinical episode that suggest multiple sclerosis. One of the signs and symptoms of CIS is Optic neuritis (ON). Several early intervention drugs are being tested in clinical trials for the early intervention in CIS patients which may lead to multiple sclerosis (MS). This study aim (1) early intervention of the CIS progression to MS delay slow down the MS progression, (2) since that ON affects 30%-70% of MS patients, the available ON intervention delay the MS progression. PubMed was used as a search engine. Summary relative risks (RRs) and 95 % confidence intervals (CIs) were estimated using a random-effect model. For aim 1, it showed lower risk of progression to MS compared to non-treated group (Risk Ratio (RR) 0.64; 95%CI: 0.58, 0.69; < 0.001). For aim 2, drug treated group showed lower risk of progression compared to non-treated group (RR 0.19, 95%CI: 0.06, 0.54, < 0.002. Statistical heterogeneity was not significant in both outcomes and bias of publication was not found using inspection of funnel plot and Egger's statistical test in both outcomes. In conclusion, early treatment should be considered in CIS patients to prevent the progression of MS. Moreover, this data shows that early intervention (Erythropoietin, Ery) of ON decreases the conversion risk to MS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1120672120983179 | DOI Listing |
Neurol Neurochir Pol
January 2025
Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland.
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that is usually diagnosed between the ages of 20 and 40. Changes in the immune system also observed in cancer may suggest a higher prevalence of cancer in the MS patient population. In recent years, many highly effective immunosuppressive drugs have been introduced into disease-modifying therapy (DMT) which may be associated with a higher risk of cancer development in patients with MS.
View Article and Find Full Text PDFJ Educ Health Promot
November 2024
Department of Neurologist, Neurologist Research Center, Faculty of Medical Sciences, Isfahan, Iran.
Background: Multiple sclerosis is a central neurogenic demyelinating disease. This is one of the most common neurological diseases in humans and is the most debilitating at a young age. Symptoms of multiple sclerosis include vision problems, balance problems, dizziness, sensory disturbances, chronic neuropathy, and fatigue.
View Article and Find Full Text PDFJ Educ Health Promot
November 2024
Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran.
Background: Multiple sclerosis and its progressive relapsing-remitting nature for MS patients is challenging and significantly affects the mental health of people with MS. We examined the direct effects of alexithymia and attachment on mental health and the indirect effect of attachment, alexithymia, loneliness, and perceived social support on the mental health of people with MS.
Materials And Methods: Three hundred and forty-five diagnosed with multiple sclerosis (MS) were deemed eligible for inclusion in the study and selected through the Iranian MS Association.
Lancet Reg Health Eur
January 2025
Department of Neurology, St. Josef-Hospital - Katholisches Klinikum Bochum, Ruhr University Bochum, Gudrunstr. 56, 44791, Bochum, Germany.
Background: In recent decades, relapsing remitting multiple sclerosis (MS) became more treatable through new disease-modifying therapies (DMTs). Identifying safe treatments with minimal fetal risks for family planning is needed.
Methods: In this prospective cohort from the German MS and Pregnancy Registry (DMSKW), we analyzed pregnancy and neonatal outcomes in MS-patients using descriptive statistics and logistic/linear regression models to compare DMT-exposed pregnancies to DMT-unexposed pregnancies.
Front Neurol
December 2024
Nordic Bioscience, Herlev, Denmark.
Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system (CNS). There is a significant delay in diagnosing MS as the symptoms and tests overlap with other diseases. Blood-based biomarkers, which quantify fragments of proteins involved in MS pathophysiology, have the potential as diagnostic biomarkers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!